New COVID booster vaccine shows promise in early trial
NCT ID NCT07134725
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new COVID-19 booster vaccine called SpiN-Tec in 432 healthy adults aged 18 to 85 who had already received full vaccination and at least one booster. The vaccine was compared to approved boosters like Covishield and Comirnaty. The goal was to check safety and whether it triggers a strong immune response. The trial has been completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SpiN-Tec MCTI UFMG vaccine (chimeric recombinant protein with adjuvant)
What this could lead to
If successful, this could provide a new booster option against COVID-19 that is safe and triggers a strong immune response.
What could go wrong
This is an early first-in-human trial with a small sample size. The vaccine may not prove as effective as existing boosters, and long-term safety is not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculdade de Medicina da UFMG - Unidade de Pesquisa Clínica em Vacinas (UPqVac)
Belo Horizonte, Minas Gerais, 30130-100, Brazil